Pancreatic cancers are classified as either exocrine or endocrine tumors depending on which type of tissue they arise from within the gland. Endocrine tumors of the pancreas are very rare, accounting for only 5% of all pancreatic cancers. The majority of endocrine pancreatic tumors are functional adenocarcinomas that overproduce a specific hormone. Pancreatic cancer is a devastating disease and has an extremely poor prognosis. Most patients die within a year of diagnosis and the overall 5-year survival rate is < 1% despite the use of extensive treatment approaches, including surgery, chemotherapy, and radiation. Therefore, innovative anti-tumor therapies for this group of patients is of a great significance. Recent preclinical and clinical studies demonstrated that immunotherapy, in particular vaccination with dendritic cells (DCs) loaded with tumor antigens, is a potential approach with promising anti-tumor effects. Therefore, augmenting the efficacy of immunotherapy with DCs would significantly improve the health of this group of patients. One strategy to augment DC-based vaccination is the use of potent adjuvants that can induce the full activation and maturation of the injected antigen-loaded DCs and their migration to the tumor draining lymph nodes, the site of antigen recognition by T cells. One of the most potent adjuvants is the microbial products that are recognized by more than 13 toll-like receptors expressed on DCs. This review article will highlight the use of DC-based vaccination toward pancreatic cancer and how it can be augmented by toll-like receptor agonists.
Keywords: Dendritic cells, immunotherapy, pancreatic cancer, T cells, Toll-like-receptor, TLR, vaccination
Hypovitaminosis D is Associated with Endothelial Dysfunction in Patients with Metabolic Syndrome
Current Vascular Pharmacology Which Dose of Folic Acid Should Pregnant Diabetic Women Receive?
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Under Re-organization) Effect of Infertility on the Sexual Function of Couples: State of the Art
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Under Re-organization) Bullous Pemphigoid and Neurologic Diseases: Toward a Specific Serologic Profile?
Endocrine, Metabolic & Immune Disorders - Drug Targets Free Fatty Acids-Sensing G Protein-Coupled Receptors in Drug Targeting and Therapeutics
Current Medicinal Chemistry Melatonin Effects on Plasmodium Life Cycle: New Avenues for Therapeutic Approach
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Under Re-organization) Modulation of T-cell Mediated Immunity by Dopamine Receptor D5
Endocrine, Metabolic & Immune Disorders - Drug Targets Synthesis, Characterization and Biological Activity of Chemically Modified Insulin Derivative with Alpha Lipoic Acid
Protein & Peptide Letters Antineoplastic Effects of PPARγ Agonists, with a Special Focus on Thyroid Cancer
Current Medicinal Chemistry Reactive Species, Cellular Repair and Risk Factors in the Onset of Type 2 Diabetes Mellitus: Review and Hypothesis
Current Diabetes Reviews Relationship between Diabetes Mellitus and Coronary Heart Disease
Current Diabetes Reviews Targeting the Type I Insulin-Like Growth Factor System for Breast Cancer Therapy
Current Drug Targets Is Fast Food Addictive?
Current Drug Abuse Reviews Potential Role of TRAIL in the Management of Autoimmune Diabetes Mellitus
Current Pharmaceutical Design Polymorphisms of the Aldose Reductase Gene and Susceptibility to Diabetic Microvascular Complications
Current Medicinal Chemistry Recent Patents on Oral Vaccine Design
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Under Re-organization) Adipose Tissue in the Regulation of Inflammation
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Under Re-organization) HDL - Cholesterol: The New Target for Treatment
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Under Re-organization) Possible Hypoxia Signaling Induced Alteration of Glucose Homeostasis in Rats Exposed to Chronic Intermittent Hypoxia - Role of Antioxidant (Vitamin C) and Ca2+ Channel Blocker (Cilnidipine)
Current Signal Transduction Therapy Leptin and Vascular Smooth Muscle Cells
Current Pharmaceutical Design